Immune Regulation News Volume 3.31 | Aug 26 2011

Control of T_H17/T_reg Balance by Hypoxia-Inducible Factor 1
Here, investigators show that hypoxia-inducible factor 1, a key metabolic sensor, regulates the balance between regulatory T cell and T_H17 differentiation. [Cell]

Gene Therapy Success for Children Born Without Functioning Immune System
Two papers report success in two established gene therapy programmes to cure children born unable to fight infection. [Press release from Great Ormond Street Hospital for Children NHS Trust discussing online prepublication in Science Translational Medicine]

Novel Cytokine Protects Mice from Colitis
Researchers have discovered that expression of a newly identified human cytokine – Interleukin 37 – protects mice from colitis. [Press release from the University of California, San Diego discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Rare Immune Cell Is Asset and Liability in Fighting Infection
Scientists reveal that the cells, known as CD8 alpha+ dendritic cells, can help the body beat back infection by a common parasite, but the same cells can be hijacked by a bacterium to decimate the body’s defenses. [Press release from Washington University in St. Louis discussing online prepublication in Immunity]

The Opposing Roles of the Transcription Factor E2A and its Antagonist Id3 that Orchestrate and Enforce the Naive Fate of T Cells
Here researchers demonstrate that Id3 expression was higher beyond the precursor to the T cell antigen receptor checkpoint, remained high in naive T cells and showed a bimodal pattern in the effector-memory population. [Nat Immunol]

CD8⁺ Cellular Immunity Mediates rAd5 Vaccine Protection Against Ebola Virus Infection of Nonhuman Primates
The findings indicate that CD8⁺ cells have a major role in recombinant adenovirus virus serotype 5-glycoprotein–induced immune protection against Ebola virus infection in nonhuman primates. [Nat Med]

Genome-Wide Analyses of Transcription Factor GATA3-Mediated Gene Regulation in Distinct T Cell Types
To understand GATA3-mediated gene regulation, investigators identified genome-wide GATA3 binding sites in ten well-defined developmental and effector T lymphocyte lineages. [Immunity]

CD8α⁺ Dendritic Cells Are the Critical Source of Interleukin-12 that Controls Acute Infection by Toxoplasma gondii Tachyzoites
Researchers examined Toxoplasma gondii infection of Batf3^-/- mice, which selectively lack only lymphoid-resident CD8α⁺ dendritic cells (DCs) and related peripheral CD103⁺ DCs. [Immunity]

CD8α⁺ Dendritic Cells Are an Obligate Cellular Entry Point for Productive Infection by Listeria monocytogenes
Although the loss of CD8α⁺ dendritic cells (DCs) in Batf3^-/- mice increases their susceptibility to several pathogens, researchers observed that Batf3^-/- mice exhibited enhanced resistance to the intracellular bacterium Listeria monocytogenes. [Immunity]

Interleukin 37 Expression Protects Mice from Colitis
In the present study, investigators examined a role for IL-37 during experimental colitis. [Proc Natl Acad Sci USA]

Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency
Gene therapy for X-linked severe combined immunodeficiency without myelosuppressive conditioning effectively restored T cell immunity and was associated with high survival rates for up to 9 years. [Sci Transl Med]

Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction
Gene therapy for adenosine deaminase severe combined immunodeficiency is safe, with effective immunological and metabolic correction, and may offer a viable alternative to conventional unrelated donor hematopoietic stem cell transplantation. [Sci Transl Med]

Allos Therapeutics Initiates Phase III Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Allos Therapeutics, Inc. announced the enrollment of the first patient in a Phase III randomized clinical trial (PDX-017) evaluating FOLOTYN(R) (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma. [Allos Therapeutics, Inc. Press Release]

Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(TM) in CD30-Positive Non-Hodgkin Lymphoma
Seattle Genetics, Inc. announced that it has initiated a phase II clinical trial of ADCETRIS(TM) (brentuximab vedotin) for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. [Seattle Genetics, Inc. Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW World Antibody Drug Conjugate Summit
October 25-28, 2011
San Francisco, United States

Visit our events page to see a complete list of events in the immune regulation community.

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies) 

Research and Development Technologist (STEMCELL Technologies) 

Proteomics, Vascular Biology/Angiogenesis, or Immunology (St.Michael’s Hospital/University of Toronto)

PhD Scholarship (Tasmania University)

Associate Director, Immune Cell Signaling (Genentech)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.